STOCK TITAN

Alkermes Inc. plc - $ALKS STOCK NEWS

Welcome to our dedicated page for Alkermes plc news (Ticker: $ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes plc stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alkermes plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alkermes plc's position in the market.

Rhea-AI Summary
Independent proxy advisory firm ISS recommends shareholders support Sarah Schlesinger for the board of Alkermes plc. They advise withholding support from cancer specialist Richard Gaynor due to an upcoming oncology spin. Sarissa Capital Management issues a presentation advocating for shareholder representation. Shareholders are urged to vote in favor of Sarissa Nominees and against executive compensation. Contact D.F. King & Co., Inc. for assistance with voting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
-
Rhea-AI Summary
Alkermes' seven independent directors issue a letter to shareholders ahead of the upcoming Annual General Meeting, recommending that shareholders vote 'FOR' the director nominees. The directors highlight their achievements and the company's strong performance, including a 49% increase in share price since the announcement of the Value Enhancement Plan. They emphasize the strategic priorities for driving value, such as the successful launch of LYBALVI® and the planned separation of the oncology business. The directors express disagreement with ISS's recommendation to vote against Dr. Gaynor's re-election.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
none
-
Rhea-AI Summary
Alkermes urges shareholders to vote for the re-election of its current board of directors at the upcoming Annual General Meeting. The board highlights their qualifications and experience, as well as the company's share price increase of 49% and outperformance compared to peers. They believe the proposed candidates from Sarissa Capital Management would not bring new skills to the board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
none
Alkermes Inc. plc

Nasdaq:ALKS

ALKS Rankings

ALKS Stock Data

4.04B
158.79M
1.25%
108.01%
8.58%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
DUBLIN 4

About ALKS

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.